Download PDF
Semin Neurol 2004; 24(1): 41-48
DOI: 10.1055/s-2004-829586
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Management of Myasthenia Gravis

David S. Saperstein1 , Richard J. Barohn2
  • 1Assistant Professor, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas
  • 2Professor and Chairman, Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas
Further Information

Publication History

Publication Date:
01 July 2004 (online)

    Permissions and Reprints

Although once a severe and often fatal illness, myasthenia gravis can now be well managed with several relatively safe and effective therapies. Management involves a graded approach, beginning with cholinesterase inhibitors for mild symptoms and advancing to immunomodulating medications for more severe weakness. There are several immunomodulating agents from which to choose; selection is based largely on time to clinical effect and adverse effects. This review will discuss the selection and use of therapies for patients with myasthenia gravis.

KEYWORDS

Myasthenia gravis - immunosuppressant - IVIg - plasmapheresis - thymectomy

REFERENCES

  • 1 Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis.  Crit Care Med. 1997;  25 1228-1235
    CrossrefPubMedGoogle Scholar
  • 2 Mayer S A, Thomas C E. Therapy of myasthenic crisis.  Crit Care Med. 1998;  26 1136-1137
    PubMedGoogle Scholar
  • 3 Tindall R SA. Humoral immunity in myasthenia gravis: effect of steroids and thymectomy.  Neurology. 1980;  30 554-557
    PubMedGoogle Scholar
  • 4 Warmolts J R, Engel W K. Benefit from alternate-day prednisone in myasthenia gravis.  N Engl J Med. 1972;  286 17-20
    CrossrefPubMedGoogle Scholar
  • 5 Pascuzzi R M, Coslett H B, Johns T R. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients.  Ann Neurol. 1984;  15 291-298
    CrossrefPubMedGoogle Scholar
  • 6 Johns T R. Long-term corticosteroid treatment of myasthenia gravis.  Ann N Y Acad Sci. 1984;  505 568-583
    PubMedGoogle Scholar
  • 7 Miller R G, Milner-Brown S, Mirka A. Prednisone-induced worsening of neuromuscular function in myasthenia gravis.  Neurology. 1986;  36 729-732
    PubMedGoogle Scholar
  • 8 Seybold M E, Drachman D B. Gradually increasing doses of prednisone in myasthenia gravis: reducing the hazards of treatment.  N Engl J Med. 1974;  290 81-84
    CrossrefPubMedGoogle Scholar
  • 9 Saperstein D S, Amato A A, Katz J S, Barohn R J. Immune mediated polyneuropathies. In: Pourmand R Neuromuscular Diseases: Expert Clinicians' Views. Boston; Butterworth-Heinemann 2001: 135-198
    Google Scholar
  • 10 Saag K G, Emkey R, Schnitzer T J et al.. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.  N Engl J Med. 1998;  339 292-299
    CrossrefPubMedGoogle Scholar
  • 11 Mantegazza R, Antozzi C, Peluchitte D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis.  J Neurol. 1988;  235 449-453
    CrossrefPubMedGoogle Scholar
  • 12 Myasthenia Gravis Clinical Study Group . A randomized clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis.  J Neurol Neurosurg Psychiatry. 1993;  53 1157-1163
    PubMedGoogle Scholar
  • 13 Matell G. Immunosuppressive drugs: azathioprine in the treatment of myasthenia gravis.  Ann N Y Acad Sci. 1987;  505 588-594
    PubMedGoogle Scholar
  • 14 Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka K V. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis.  Neurology. 1988;  38 258-261
    PubMedGoogle Scholar
  • 15 Mertens H G, Hertel P, Reuther P, Ricker K. Effect of immunosuppressive drugs (Azathioprine).  Ann N Y Acad Sci. 1981;  337 691-699
    PubMedGoogle Scholar
  • 16 Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.  Neurology. 1998;  50 1778-1783
    CrossrefPubMedGoogle Scholar
  • 17 Kissel J T, Levy R J, Mendell J R, Griggs R C. Azathioprine toxicity in neuromuscular disease.  Neurology. 1986;  36 35-39
    CrossrefPubMedGoogle Scholar
  • 18 Herrlinger U, Weller M, Dichgans J, Melms A. Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis.  Ann Neurol. 2000;  47 682-683
    PubMedGoogle Scholar
  • 19 Tindall R SA, Phillips J T, Rollins J A, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis.  Ann N Y Acad Sci. 1993;  681 539-551
    CrossrefPubMedGoogle Scholar
  • 20 Tindall R SA, Rollins J A, Phillips J T, Greenlee R G, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.  N Engl J Med. 1987;  316 719-724
    CrossrefPubMedGoogle Scholar
  • 21 Ciafaloni E, Nikhar N K, Massey J M, Sanders D B. Retrospective analysis of the use of cyclosporine in myasthenia gravis.  Neurology. 2000;  55 448-450
    CrossrefPubMedGoogle Scholar
  • 22 Ciafaloni E, Massey J M, Tucker-Lipscomb B, Sanders D B. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.  Neurology. 2001;  56 97-99
    CrossrefPubMedGoogle Scholar
  • 23 Chaudhry V, Cornblath D R, Griffin J W, O'Brien R, Drachman D B. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.  Neurology. 2001;  56 94-96
    CrossrefPubMedGoogle Scholar
  • 24 Meriggioli M N, Ciafaloni E, Al-Hayk K A et al.. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.  Neurology. 2003;  61 1438-1440
    CrossrefPubMedGoogle Scholar
  • 25 Meriggioli M N, Rowin J, Richman J G, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study.  Ann N Y Acad Sci. 2003;  998 494-499
    CrossrefPubMedGoogle Scholar
  • 26 Haberal M, Karakayali H, Emiroglu R, Basaran O, Moray G, Bilgin N. Malignant tumors after organ transplantation.  Artif Organs. 2002;  26 778-781
    CrossrefPubMedGoogle Scholar
  • 27 Perez M C, Buot W L, Mercado-Danguilan C, Bagabaldo Z G, Renales L D. Stable remissions in myasthenia gravis.  Neurology. 1981;  31 32-37
    CrossrefPubMedGoogle Scholar
  • 28 De Feo L G, Schottlender J, Martelli N A, Molfino N A. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis.  Muscle Nerve. 2002;  26 31-36
    CrossrefPubMedGoogle Scholar
  • 29 Drachman D B, Jones R J, Brodsky R A. Treatment of refractory myasthenia: “rebooting” with high-dose cyclophosphamide.  Ann Neurol. 2003;  53 29-34
    CrossrefPubMedGoogle Scholar
  • 30 Dau P C, Lindstrom J M, Cassel C K, Denys E H, Shev E E, Spitler L E. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.  N Engl J Med. 1977;  297 1134-1140
    CrossrefPubMedGoogle Scholar
  • 31 Arsura E. Experience with intravenous immunoglobulin in myasthenia gravis.  Clin Immunol Immunopathol. 1989;  53 S170-S179
    CrossrefPubMedGoogle Scholar
  • 32 Fateh-Moghadam A, Wick M, Besinger U, Geursen R G. High-dose intravenous gammaglobulin for myasthenia gravis.  Lancet. 1984;  1 848-849
    PubMedGoogle Scholar
  • 33 Gajdos P, Outin H, Elkharrat D et al.. High-dose intravenous gammaglobulin for myasthenia gravis.  Lancet. 1984;  1 406-407
    PubMedGoogle Scholar
  • 34 Cosi V, Lombardi M, Piccolo G, Erbetta A. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin.  Acta Neurol Scand. 1991;  84 81-84
    PubMedGoogle Scholar
  • 35 Dalakas M C. Experience with IVIg in the treatment of patients with myasthenia gravis.  Neurology. 1997;  48(suppl 5) S64-S69
    PubMedGoogle Scholar
  • 36 Achiron A, Barak Y, Miron S, Sarova-Pinhas I. Immunoglobulin treatment in refractory myasthenia gravis.  Muscle Nerve. 2000;  23 551-555
    CrossrefPubMedGoogle Scholar
  • 37 Jongen J L, van Doorn P A, van der Meche F G. High-dose intravenous immunoglobulin therapy for myasthenia gravis.  J Neurol. 1998;  245 26-31
    PubMedGoogle Scholar
  • 38 Liblau R, Gajdos P, Bustarret F A et al.. Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies.  J Clin Immunol. 1991;  11 128-131
    CrossrefPubMedGoogle Scholar
  • 39 Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. for the Myasthenia Gravis Clinical Study Group . Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis.  Ann Neurol. 1997;  41 789-796
    CrossrefPubMedGoogle Scholar
  • 40 Qureshi A I, Choudhry M A, Akbar M S et al.. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.  Neurology. 1999;  52 629-632
    CrossrefPubMedGoogle Scholar
  • 41 Stricker R B, Kwiatkowska B J, Habis J A, Kiprov D D. Myasthenic crisis: response to plasmapheresis following failure of intravenous gamma-globulin.  Arch Neurol. 1993;  50 837-840
    CrossrefPubMedGoogle Scholar
  • 42 Wolfe G I, Barohn R J, Foster B M et al.. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.  Muscle Nerve. 2002;  26 549-552
    CrossrefPubMedGoogle Scholar
  • 43 Tan E, Hajinazarian M, Bay W, Neff J, Mendell J R. Acute renal failure resulting from intravenous immunoglobulin therapy.  Arch Neurol. 1993;  50 137-139
    PubMedGoogle Scholar
  • 44 Steg R E, Lefkowitz D M. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis.  Neurology. 1994;  44 1180-1181
    PubMedGoogle Scholar
  • 45 Caress J B, Cartwright M S, Donofrio P D, Peacock Jr J E. The clinical features of 16 cases of stroke associated with administration of IVIg.  Neurology. 2003;  60 1822-1824
    CrossrefPubMedGoogle Scholar
  • 46 Blalock A, Mason M F, Morgan H J et al.. Myasthenia gravis and tumors of the thymic region. Report of a case in which the tumor was removed.  Ann Surg. 1939;  110 544-561
    CrossrefPubMedGoogle Scholar
  • 47 Gronseth G S, Barohn R J. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2000;  55 7-15
    CrossrefPubMedGoogle Scholar
  • 48 Mantegazza R, Baggi F, Antozzi C et al.. Myasthenia gravis (MG): epidemiological data and prognostic factors.  Ann N Y Acad Sci. 2003;  998 413-423
    CrossrefPubMedGoogle Scholar
  • 49 Perlo V P, Arnason B, Poskanzer D et al.. The role of thymectomy in the treatment of myasthenia gravis.  Ann N Y Acad Sci. 1971;  183 308-315
    PubMedGoogle Scholar
  • 50 Rodriguez M, Gomez M R, Howard Jr F M, Taylor W F. Myasthenia gravis in children: long-term follow-up.  Ann Neurol. 1983;  13 504-510
    CrossrefPubMedGoogle Scholar
  • 51 Mulder D G, Graves M, Herrmann C. Thymectomy for myasthenia gravis: recent observation and comparisons with past experience.  Ann Thorac Surg. 1989;  48 551-555
    PubMedGoogle Scholar
  • 52 Lanska D J. Diagnosis of thymoma in myasthenics using anti-striated muscle antibodies: predictive value and gain in diagnostic certainty.  Neurology. 1991;  41 520-524
    PubMedGoogle Scholar
  • 53 Schumm F, Wiethölter H, Fateh-Moghadam A, Dichgans J. Thymectomy in myasthenia with pure ocular symptoms.  J Neurol Neurosurg Psychiatry. 1985;  48 332-337
    PubMedGoogle Scholar
  • 54 Lanska D J. Indications for thymectomy in myasthenia gravis.  Neurology. 1990;  40 1828-1829
    CrossrefPubMedGoogle Scholar
  • 55 Grob D, Asura E L, Brunner N G, Namba T. The course of myasthenia gravis and therapies affecting outcome.  Ann N Y Acad Sci. 1987;  505 472-499
    CrossrefPubMedGoogle Scholar
  • 56 McQuillen M P, Leone M G. A treatment carol: thymectomy revisited.  Neurology. 1977;  27 1103-1106
    CrossrefPubMedGoogle Scholar
  • 57 Wolfe G I, Kaminski H J, Jaretzki III A, Swan A, Newsom-Davis J. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy.  Ann N Y Acad Sci. 2003;  998 473-480
    CrossrefPubMedGoogle Scholar
  • 58 Monden Y, Nakahara K, Kagotani K et al.. Effects of preoperative duration of symptoms on patients with myasthenia gravis.  Ann Thorac Surg. 1984;  38 287-291
    PubMedGoogle Scholar
  • 59 DeFilippi V J, Richman D P, Ferguson M K. Transcervical thymectomy for myasthenia gravis.  Ann Thorac Surg. 1994;  57 194-197
    PubMedGoogle Scholar
  • 60 Younger D S, Jaretzki III A, Penn A S et al.. Maximum thymectomy for myasthenia gravis.  Ann N Y Acad Sci. 1987;  505 832-835
    PubMedGoogle Scholar
  • 61 Papatestas A E, Genkins G, Kornfeld P, Horowitz S, Kark A E. Transcervical thymectomy in myasthenia gravis.  Surg Gynecol Obstet. 1975;  140 535-540
    PubMedGoogle Scholar
  • 62 Cooper J D, Al-Jilaihawa A N, Pearson F G, Humphrey H E. An improved technique to facilitate transcervical thymectomy for myasthenia gravis.  Ann Thorac Surg. 1988;  45 242-247
    CrossrefPubMedGoogle Scholar
  • 63 Yim A P, Kay R L, Ho J K. Video-assisted thoracoscopic thymectomy for myasthenia gravis.  Chest. 1995;  108 1440-1443
    CrossrefPubMedGoogle Scholar
  • 64 Sabbagh M N, Garza J JS, Patten B. Thoracoscopic thymectomy in patients with myasthenia gravis.  Muscle Nerve. 1995;  18 1475-1477
    CrossrefPubMedGoogle Scholar
  • 65 Mack M J, Landreneau R J, Yim A P, Hazelrigg S R, Scruggs G R. Results of video-assisted thymectomy in patients with myasthenia gravis.  J Thorac Cardiovasc Surg. 1996;  112 1352-1359
    CrossrefPubMedGoogle Scholar
  • 66 Batra P, Herrmann Jr C, Mulder D. Mediastinal imaging in myasthenia gravis: correlation of chest radiography, CT, MR, and surgical findings.  AJR Am J Roentgenol. 1987;  148 515-519
    PubMedGoogle Scholar
  • 67 Nations S P, Wolfe G I, Amato A A, Jackson C, Bryan W W, Barohn R J. Myasthenia gravis developing after removal of thymoma.  J Child Neurol. 1997;  12 133
    PubMedGoogle Scholar
  • 68 Yoshikawa H, Mabuchi K, Yasukawa Y, Takamori M, Yamada M. Low-dose tacrolimus for intractable myasthenia gravis.  J Clin Neurosci. 2002;  9 627-628
    CrossrefPubMedGoogle Scholar
  • 69 Evoli A, Di Schino C, Marsili F, Punzi C. Successful treatment of myasthenia gravis with tacrolimus.  Muscle Nerve. 2002;  25 111-114
    CrossrefPubMedGoogle Scholar
  • 70 De Mattos A M, Olyaei A J, Bennett W M. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future.  Am J Kidney Dis. 2000;  35 333-346
    CrossrefPubMedGoogle Scholar
  • 71 Wylam M E, Anderson P M, Kuntz N L, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report.  J Pediatr. 2003;  143 674-677
    CrossrefPubMedGoogle Scholar
  • 72 Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant.  Neurology. 2000;  55 1062-1063
    PubMedGoogle Scholar
  • 73 Scuderi F, Marino M, Colonna L et al.. Anti-P110 autoantibodies identify a subtype of “seronegative” myasthenia gravis with prominent oculobulbar involvement.  Lab Invest. 2002;  82 1139-1146
    PubMedGoogle Scholar
  • 74 Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.  Nat Med. 2001;  7 365-368
    CrossrefPubMedGoogle Scholar
  • 75 Sanders D B, El-Salem K, Massey J M, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG.  Neurology. 2003;  60 1978-1980
    CrossrefPubMedGoogle Scholar

David S SapersteinM.D. 

Assistant Professor, Department of Neurology, University of Kansas Medical Center

3901 Rainbow Blvd., Mail-stop 2012

Kansas City, KS 66160

      >